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nents over baseline. On the Bosch calculated single index,
cilostazol was better than pentoxifylline and placebo.
Pentoxifylline had a lower calculated QALY score than
cilostazol or placebo. Based on this model, cilostazol had
an incremental cost per QALY of $72,153 over placebo
and $21,294 over pentoxifylline. As expected the model
is sensitive to changes in price and utilities, and patients
who have substantial improvements in QOL scores over
baseline have better cost per QALY results. From a man-
aged care perspective with a patient co-pay of 20%, the
patient’s incremental cost of cilostazol over placebo was
$14,431 per QALY and the managed care plan cost is
$57,722 per QALY. CONCLUSION: Based on this anal-
ysis of treatments for intermittent claudication, cilostazol
had a reasonable incremental cost per QALY over pen-
toxifylline or placebo. Lower cost per QALY results can
be obtained by continuing on therapy patients who attain
higher than average gains in quality of life scores from
baseline.
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OBJECTIVE: Patient compliance is an important com-
ponent in the successful management of any disease. In
general, it is assumed that in disease states involving peri-
odic, intense pain, such as angina pectoris (AP), com-
pliance rates would be high, and unaffected by dosing
regimen. We verified this hypothesis by examining the
compliance rates of patients taking different formulations
(o.d. (200–300mg), b.d. (90–120mg) and t.d.s. (60mg))
of diltiazem (princeps) for AP. METHOD: We performed
a retrospective analysis of 3455 electronic patient records
with a diagnosis of AP and a prescription of diltiazem
(princeps) from June 1st 1997 to June 1st 1998 (Medi-
plus-IMS Health) with a one-year follow-up. The above
patient cohort was then divided into 3 subgroups accord-
ing to the different formulation taken. The two sub-
groups b.d. and t.d.s. were paired to the third one, ac-
cording to 4 criteria: age, sex, disease history and co-
morbidities. Compliance was assessed using initial pre-
scription and refill rates ((pills dispensed/daily dose)/du-
ration of therapy). RESULTS: The proportion of patients
showing “good compliance” ( 0.8) was significantly
higher for the o.d. versus b.d. (36.1% versus 25.9%, p 
0.001) and for the o.d. versus t.d.s. (36.1% versus
27.1%, p  0.008). We observed the same trend when
we compared the mean rate of compliance for the o.d.
versus b.d. (0.62 versus 0.55, p  0.0027) and for the
o.d. versus t.d.s. (0.62 versus 0.60, p  0.0121). CON-
CLUSION: Even for life threatening cardiac disease like
AP, dosing regimens have a significant effect on compli-
ance. Giving diltiazem as an o.d. formulation could sig-
nificantly improve compliance and potentially decrease
health care resources used.
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OBJECTIVE: To examine the cost of illness of Conges-
tive Heart Failure (CHF) in the Louisiana Medicaid pro-
gram. METHODS: Study design: A retrospective review
of the medical and pharmacy claims data (1999–2000) in
the Louisiana Medicaid program. We reviewed pharmacy
and medical claims data for the years 1999–2000 from
the Louisiana Medicaid program. The data were ob-
tained from Unisys, the fiscal intermediary for the Louisi-
ana Medicaid program, in a PC compatible format. We
extracted the claims for CHF patients on the basis of the
ICD-9-CM codes. A total of 13,947 patients met the
study criteria, which included at least one primary or sec-
ondary diagnosis of CHF and availability of claims data
for at least one year after the first CHF diagnosis related
claim. We reviewed all the charges incurred for a one-
year period after the initial CHF claim. RESULTS: The
total cost for CHF patients for one year was over $182
million. The majority of the patients (73.63%) were fe-
male and accounted for 70% of the total cost. The mean
age was 70 years and the largest portion of the total cost
(55%) came from those 65 years and older. Of the
13,947 patients 11,065 (79%) were hospitalized at an
average cost of $4,679 per hospitalized patient. Approxi-
mately 87% of the study population received prescription
drugs at an average cost of $2,897 per prescription drug
user. Hospitalizations and prescription drugs contributed
28% and 19.38% respectively to the total cost. Almost
one third of the total cost was due to long-term care at
$13,817 per utilizer. Costs for CHF diagnosis related
claims were 14% of all costs. CONCLUSION: CHF rep-
resents a significant financial burden from the perspective
of the Louisiana Medicaid program. Improved manage-
ment of the condition is needed to reduce the cost of
treatment associated with CHF.
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Recent evidence suggests there is an increased risk of
rhabdomyolysis in patients initiated on cerivastatin com-
pared to patients initiated on other HMG CoA reductase
